山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (10): 120-124.doi: 10.6040/j.issn.1671-7554.0.2022.0490
• 病例报道 • 上一篇
李燕1,陈萍2,赵红玉2,杨文采1,周佩瑶1,李大启2
中图分类号:
| [1] Tomita N, Kodama F, Kanamori H, et al. Secondary central nervous system lymphoma[J]. Int J Hematol, 2006, 84(2): 128-135. [2] Tolvaj B, Hahn K, Nagy Z, et al. Life threatening rare lymphomas presenting as longitudinally extensive transverse myelitis: a diagnostic challenge[J]. Ideggyogy Sz, 2020, 73(7-8): 275-285. [3] Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkins lymphoma: a 20-year follow-up analysis of SWOG 8516-the Southwest Oncology Group[J]. J Clin Oncol, 2009, 27(1): 114-119. [4] Hollender A, Kvaloy S, Lote K, et al. Prognostic factors in 140 adult patients with non-Hodgkins lymphoma with systemic central nervous system(CNS)involvement. A single centre analysis[J]. Eur J Cancer, 2000, 36(14): 1762-1768. [5] Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkins lymphoma: a risk model[J]. Ann Oncol, 2002, 13(7): 1099-1107. [6] Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma: a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkins Lymphoma Study Group(DSHNHL)[J]. Ann Oncol, 2007, 18(1): 149-157. [7] Doolittle ND, Abrey LE, Shenkier TN, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report[J]. Blood, 2008, 111(3): 1085-1093. [8] Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial[J]. Lancet, 2009, 374(9700): 1512-1520. [9] Omuro AMP, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly[J]. J Neuro Oncol, 2007, 85(2): 207-211. [10] Wang XX, Huang HQ, Bai B, et al. Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience[J]. Leuk Lymphoma, 2014, 55(11): 2497-2501. [11] Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma[J]. Neurology, 2011, 76(10): 929-930. [12] Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy(CHOP-14)with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group(DSHNHL)[J]. Blood, 2009, 113(17): 3896-3902. [13] Kumar A, Vanderplas A, LaCasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database[J]. Cancer, 2012, 118(11): 2944-2951. [14] Houillier C, Choquet S, Touitou V, et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma[J]. Neurology, 2015, 84(3): 325-326. [15] Rubenstein JL, Geng HM, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma[J]. Blood Adv, 2018, 2(13): 1595-1607. [16] Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab(REVRI)in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma(LOC)Network and the Lymphoma Study Association(LYSA)dagger[J]. Ann Oncol, 2019, 30(4): 621-628. [17] Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma[J]. Nature, 2010, 463(7277): 88-92. [18] Treanor B. B-cell receptor: from resting state to activate[J]. Immunology, 2012, 136(1): 21-27. [19] Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association(LYSA)and the French oculo-cerebral lymphoma(LOC)network[J]. Eur J Cancer, 2019, 117: 121-130. doi: 10.1016/j.ejca.2019.05.024. [20] Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia[J]. N Engl J Med, 2013, 369(1): 32-42. [21] Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia[J]. N Engl J Med, 2015, 373(25): 2425-2437. [22] Burger JA. Bruton tyrosine kinase inhibitors: present and future[J]. Cancer J, 2019, 25(6): 386-393. [23] Bond DA, Woyach JA. Targeting BTK in CLL: beyond ibrutinib[J]. Curr Hematol Malig Rep, 2019, 14(3): 197-205. [24] Yu H, Wang X, Li J, et al. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma[J]. Mol Ther Oncolytics, 2021, 21: 158-170. doi: 10.1016/j.omto.2021.03.015. [25] 宋玉琴,邓丽娟,张斌,等.奥布替尼在复发/难治原发或继发中枢神经系统淋巴瘤患者的外周血和脑脊液中药物浓度的初步结果[C] //第二十四届全国临床肿瘤学大会暨2021年CSCO学术年会.厦门:中国临床肿瘤学会(CSCO)淋巴瘤专家委员会,2021. [26] Bairey O, Siegal T. The possible role of maintenance treatment for primary central nervous system lymphoma[J]. Blood Rev, 2018, 32(5): 378-386. [27] Song Y, Song Y, Liu L, et al. Long-term safety and efficacy of orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study[J]. Blood, 2020,136(Suppl1): 1. [28] Wu JJ, Wang WH, Dong M, et al. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study[J]. Investig New Drugs, 2022, 40(3): 650-659. [29] Houillier C, Chabrot CM, Moles-Moreau MP, et al. Rituximab-lenalidomide-ibrutinib combination for relapsed/refractory primary CNS lymphoma: a case series of the LOC network[J]. Neurology, 2021, 97(13): 628-631. [30] Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma[J]. Blood, 2017, 129(23): 3071-3073. [31] Mehdizadeh S, Bayatipoor H, Pashangzadeh S, et al. Immune checkpoints and cancer development: Therapeutic implications and future directions[J]. Pathol Res Pract, 2021, 223: 153485. doi: 10.1016/j.prp.2021.153485. [32] Madabhavi IV, Revannasiddaiah S, Sarkar MS, et al. Sanctuary site central nervous system relapse-refractory DLBCL responding to nivolumab and lenalidomide[J]. Oral Oncol, 2019, 93: 122-124. doi: 10.1016/j.oraloncology.2019.04.010. |
| [1] | 聂牧,倪晓菲,秦平,杨丹丹,李强,侯明,彭军,张晓琳,石艳. 单次利妥昔单抗治疗原发免疫性血小板减少症的疗效及安全性[J]. 山东大学学报 (医学版), 2018, 56(5): 81-84. |
|
